EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Cefazolin population pharmacokinetics in children undergoing maintenance hemodialysis for kidney failure

Romain Berthaud iD, Saïk Urien, Saoussen Krid, Frantz Foissac, Mehdi Oualha, Michaël Thy, Olivia Boyer, Agathe Béranger, Déborah Hirt iD, Sihem Benaboud, Jean-Marc Tréluyer, Naïm Bouazza

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00451-25 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Romain Berthaud und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM, Pharmacologie et Evaluations des Thérapeutiques chez l'Enfant et la Femme Enceinte, Paris, France. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cefazolin, Renal Dialysis, Renal Insufficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to develop a population pharmacokinetic model of cefazolin in children undergoing maintenance hemodialysis for kidney failure and simulate dosing regimens to optimize patients’ exposure. Cefazolin plasma concentrations were quantified using high-performance liquid chromatography. A non-linear mixed-effect modeling approach was used to investigate cefazolin pharmacokinetics. Optimal dosing regimens were determined using Monte Carlo simulations targeting 100% of the time a free plasma concentration four times above the minimum inhibitory concentration (MIC) and total plasma concentration less than 80 mg/L (100% fT > 4 × MIC and C < 80 mg/L). Eighty-three samples were analyzed from six patients aged 1.3–14.6 years and weighing 11.4–51 kg. A one-compartment model with first-order elimination best fitted the data, with a significant between-subject variability (BSV). Body weight (BW), using the allometric rule, was a significant predictor of residual elimination clearance (CL) and volume of distribution (Vd), while dialysis membrane surface area (DMSA) explained almost all the BSV on dialysis clearance (CLdial). The parameter relationships were Vd i (L) = 14.6 × (BW i /70), CL i (L/h) = 0.186 × (BW i /70) 0.75 , CLdial i (L/h)=1.98 × (DMSA i /1) 1.26 , CLtot i = CL i + CLdial DMSA i , where the subscript i denotes the i th patient’s covariate value. Dosing regimens were simulated for six CL ranges, targeting two concentration intervals: 40–80 mg/L and 20–80 mg/L for MIC of 2 and 1 mg/L, respectively. In children on maintenance hemodialysis for kidney failure, due to the persistence of a large unexplained BSV on CL that substantially affects them, optimal dosing regimen would not be accurately determined a priori and should be individually determined using therapeutic drug monitoring, taking BW, DMSA, and CL into account. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT02539407 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCefazolinRenal DialysisRenal InsufficiencyAdolescentChildChild, PreschoolFemaleHumansInfantMaleMicrobial Sensitivity TestsMonte Carlo Method

Stichwörter der Autor:innen

cefazolinchildrendialysishemodialysiskidney failuremaintenancepopulation pharmacokineticsrenal replacement therapy

Substanzen

Anti-Bacterial AgentsCefazolin

Autor:innen und Institutionen

  • Université Paris Cité, INSERM, Pharmacologie et Evaluations des Thérapeutiques chez l'Enfant et la Femme Enceinte, Paris, France.
  • Centre d'Investigation Clinique 1419, Inserm, AP-HP, Hôpital Necker-Enfants Malades, Paris, France.
  • Service de Néphrologie Pédiatrique, AP-HPH, Hôpital Necker-Enfants Malades, Paris, France.
  • Unité de Recherche Clinique Necker Cochin, AP-HP, Hôpital Tarnier, Paris, France.
  • Unité de Réanimation et Surveillance Continue Pédiatrique, AP-HP, Hôpital Necker-Enfants Malades, Paris, France.
  • Université Sorbonne Paris Nord, INSERM, UMR1137 IAME, Paris, France.

ORCID-Profile: Romain Berthaud, Déborah Hirt

Zitieren

APA

Berthaud, R., Urien, S., Krid, S., Foissac, F., Oualha, M., Thy, M., Boyer, O., Béranger, A., Hirt, D., Benaboud, S., Tréluyer, J. M., & Bouazza, N. (2025). Cefazolin population pharmacokinetics in children undergoing maintenance hemodialysis for kidney failure. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00451-25

Vancouver

Berthaud R, Urien S, Krid S, Foissac F, Oualha M, Thy M, et al. Cefazolin population pharmacokinetics in children undergoing maintenance hemodialysis for kidney failure. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00451-25

BibTeX
@article{Berthaud2025,
  author = {Berthaud, Romain and Urien, Saïk and Krid, Saoussen and Foissac, Frantz and Oualha, Mehdi and Thy, Michaël and Boyer, Olivia and Béranger, Agathe and Hirt, Déborah and Benaboud, Sihem and Tréluyer, Jean-Marc and Bouazza, Naïm},
  title = {Cefazolin population pharmacokinetics in children undergoing maintenance hemodialysis for kidney failure},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00451-25}
}
Kostenlos starten →